The Moving Average Convergence Divergence (MACD) for CRSP turned positive on October 28, 2026. Looking at past instances where CRSP's MACD turned positive, the stock continued to rise in 38 of 46 cases over the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CRSP as a result. In 77 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
Following a +5.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in 210 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRSP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRSP crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
CRSP broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRSP entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.772) is normal, around the industry mean (3.482). P/E Ratio (-10.631) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (454.545) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 70 (best 1 - 100 worst), indicating slightly worse than average price growth. CRSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GNOM advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 167 of 194 cases where GNOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
The 10-day RSI Indicator for GNOM moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 57 of 69 cases where GNOM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GNOM as a result. In 85 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for GNOM turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 48 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
GNOM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
GNOM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
CRSP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 96 | |
PRICE GROWTH RATING 1..100 | 70 | |
P/E GROWTH RATING 1..100 | 54 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| CRSP | GNOM | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 86% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 87% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 90% |
| Advances ODDS (%) | 10 days ago 82% | 4 days ago 86% |
| Declines ODDS (%) | 6 days ago 81% | 6 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRSP’s FA Score shows that 1 FA rating(s) are green while .
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRSP’s TA Score shows that 4 TA indicator(s) are bullish.
CRSP (@Biotechnology) experienced а -2.63% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.35%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -18.54%.
CRSP is expected to report earnings on Feb 16, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, GNOM has been closely correlated with TWST. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if GNOM jumps, then TWST could also see price increases.
| Ticker / NAME | Correlation To GNOM | 1D Price Change % | ||
|---|---|---|---|---|
| GNOM | 100% | +1.04% | ||
| TWST - GNOM | 74% Closely correlated | +0.15% | ||
| CRSP - GNOM | 72% Closely correlated | +3.11% | ||
| MRNA - GNOM | 68% Closely correlated | +5.27% | ||
| TXG - GNOM | 66% Loosely correlated | +2.10% | ||
| NTRA - GNOM | 62% Loosely correlated | -14.59% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPYU | 27.55 | 0.25 | +0.92% |
| MAX S&P 500 4X Leveraged ETN (SPYU) | |||
| GVLE | 48.33 | 0.11 | +0.22% |
| Goldman Sachs Value Opportunities ETF (GVLE) | |||
| CBOO | 24.25 | -0.03 | -0.12% |
| Calamos Bitcoin Structured Alt Protection ETF - October (CBOO) | |||
| BCI | 24.64 | -0.06 | -0.24% |
| abrdn Bloomberg All Commodity Strategy K-1 Free ETF (BCI) | |||
| SIXS | 56.85 | -0.75 | -1.29% |
| ETC 6 Meridian Small Cap Equity ETF (SIXS) | |||